Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SGMS1 | Q86VZ5 | 3/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31668267 | 0.88 | HTR6 (0.49) | GPR119HTR6BCHEKDM4EPKM | |
| SCHEMBL4002091 | 0.85 | GPR119 (0.48) | GPR119HTR6BCHEKDM4EPKM | |
| SCHEMBL4297962 | 0.83 | HTR6 (0.39) | GPR119HTR6BCHEKDM4EPKM | |
| SCHEMBL4306614 | 0.83 | GPR119 (0.44) | GPR119KDM4EPKMFAAH | |
| SCHEMBL4171410 | 0.79 | GPR119 (0.43) | GPR119FAAH | |
| SCHEMBL8696526 | 0.76 | GPR119 (0.58) | GPR119HTR6KDM4EPKMFAAH | |
| SCHEMBL26116198 | 0.74 | HTR6 (0.48) | GPR119HTR6BCHEKDM4EPKM | |
| SCHEMBL31668317 | 0.74 | HTR6 (0.48) | GPR119HTR6BCHEKDM4EPKM | |
| SCHEMBL5819743 | 0.73 | ALDH1A1 (0.43) | GPR119HTR6BCHEKDM4EPKM | |
| SCHEMBL31668261 | 0.73 | HTR6 (0.47) | GPR119HTR6BCHEKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084466-B2 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-27 | — | — | US | disclosed |
| WO-2009079001-A1 | BICYCLIC HETEROARYL-SUBSTITUTED IMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | HRH4, HRH3, HRH1 | GPR119 377/4885HTR6 151/4885BCHE 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.